+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antibody Therapeutics Market by Antibody Type (Antibody Fragments, Antibody-Drug Conjugates (ADCs), Bispecific Antibody), Route of Administration (Intravenous, Subcutaneous), Source, Disease Areas, Application, End-User - Global Forecast 2025-2030- Product Image
Antibody Therapeutics Market by Antibody Type (Antibody Fragments, Antibody-Drug Conjugates (ADCs), Bispecific Antibody), Route of Administration (Intravenous, Subcutaneous), Source, Disease Areas, Application, End-User - Global Forecast 2025-2030- Product Image
Sale

Antibody Therapeutics Market by Antibody Type (Antibody Fragments, Antibody-Drug Conjugates (ADCs), Bispecific Antibody), Route of Administration (Intravenous, Subcutaneous), Source, Disease Areas, Application, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5924893
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The antibody therapeutics market is evolving rapidly, driven by scientific breakthroughs, advanced manufacturing, and expanding clinical applications. Senior decision-makers must navigate an increasingly sophisticated and collaborative landscape as antibody-based solutions transform treatment paradigms and reshape the competitive landscape.

Market Snapshot: Antibody Therapeutics Growth Trajectory

The Antibody Therapeutics Market grew from USD 256.28 billion in 2024 to USD 287.58 billion in 2025. It is expected to continue growing at a CAGR of 12.45%, reaching USD 518.32 billion by 2030. Driven by molecular engineering advances, digital technologies, and increased intersectoral collaboration, the sector continues to offer innovation across oncology, immunology, and rare diseases. Diverse regulatory conditions, emerging markets, and changing trade dynamics further contribute to the shifting global market landscape.

Scope & Segmentation: Key Dimensions in Antibody Therapeutics

  • Antibody Types: Antibody fragments, antibody-drug conjugates, bispecific antibodies, monoclonal antibodies, polyclonal antibodies
  • Routes of Administration: Intravenous and subcutaneous approaches, supporting both hospital-based and outpatient treatments
  • Source Origins: Chimeric, humanized, and fully human antibodies reflecting evolving safety and efficacy priorities
  • Disease Areas: Oncology, autoimmune and inflammatory diseases, neurology, hematology, immunology, osteology, rare disorders
  • Applications: Diagnostics, research, and therapeutic interventions across patient populations
  • End-Users: Hospitals, research institutes, and specialty clinics determining adoption and procurement pathways
  • Regions: Americas, Europe Middle East & Africa, and Asia-Pacific, each with unique regulatory and commercialization landscapes; further segmenting into major countries such as the United States, Canada, Brazil, Germany, China, Japan, and others
  • Leading Companies: Representatives include AbbVie, Amgen, AstraZeneca, Bayer, Biogen, Johnson & Johnson, Novartis, Pfizer, Sanofi, Takeda, and key biotechs such as Adaptimmune Therapeutics, Antikor Biopharma, and Xencor
  • Technological Innovations: Integration of artificial intelligence in antibody design, advanced molecular platforms, and digital manufacturing

Key Takeaways: Strategic Insights for Decision Makers

  • New modalities such as bispecific antibodies and antibody-drug conjugates are reshaping treatment approaches, offering improved selectivity and outcomes for complex diseases.
  • Digital technologies are accelerating candidate identification and optimizing manufacturing, driving efficiency gains and reducing development timelines.
  • Collaborative models involving biotechs, large pharma, academic centers, and contract manufacturers foster portfolio diversification and risk mitigation.
  • Regulatory adaptation is essential, as frameworks evolve to address biologic complexity and expedite market entry.
  • Disease and application diversity—from oncology to diagnostics—require tailored go-to-market strategies and robust evidence generation.
  • Regional differences in healthcare systems, intellectual property, and policy landscapes shape partnership and expansion decisions.

Tariff Impact: Navigating Trade Policy Shifts

Upcoming U.S. tariff policies in 2025 are expected to increase costs and disrupt supply chains due to reliance on foreign-sourced reagents and raw materials. Companies are proactively re-evaluating suppliers, sourcing options, and logistics to preserve continuity and mitigate pricing volatility. Adjustments may involve vertical integration and greater reliance on regional production facilities, as well as enhanced inventory management to address new lead times and compliance challenges.

Methodology & Data Sources

This analysis is built upon rigorous primary research through interviews with industry leaders and validated by secondary sources, including peer-reviewed journals, regulatory publications, and conference materials. Data cross-referencing and expert reviews reinforce integrity, supporting a balanced view of scientific and market developments.

Why This Report Matters

  • Delivers actionable insights to inform R&D, investment, and commercial strategies in a highly dynamic market.
  • Maps key segmentation, emerging technologies, and region-specific nuances, supporting confident, data-driven decisions for global expansion and operational excellence.
  • Enables stakeholders to anticipate supply chain risks, regulatory shifts, and partnership opportunities.

Conclusion

Antibody therapeutics continue to drive medical innovation and strategic industry shifts. Senior executives equipped with this intelligence can proactively capture new opportunities, mitigate disruption, and steer sustainable growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of bispecific and multispecific antibody pipelines targeting solid tumors with enhanced efficacy profiles
5.2. Rising adoption of antibody-drug conjugates with novel payload linkers for refractory cancers
5.3. Integration of AI-driven antibody design accelerating discovery of next-generation cancer therapeutics
5.4. Surge in regulatory approvals for checkpoint inhibitor antibodies across diverse oncology indications
5.5. Emergence of personalized antibody therapies guided by patient-specific antigen profiling and biomarker analysis
5.6. Accelerated FDA and EMA regulatory clearances for checkpoint inhibitor antibodies across rare cancer subtypes
5.7. Strategic partnerships accelerate innovation in antibody drug development
5.8. Emergence of chemo-enzymatic antibody conjugation methods enabling site-specific payload attachment with improved therapeutic index
5.9. Increased venture funding fuels development of multi-targeted antibody therapeutics for resistant tumor microenvironments
5.10. Strategic collaborations between biotech startups and big pharma catalyzing next-generation multivalent antibody constructs
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antibody Therapeutics Market, by Antibody Type
8.1. Introduction
8.2. Antibody Fragments
8.3. Antibody-Drug Conjugates (ADCs)
8.4. Bispecific Antibody
8.5. Monoclonal Antibody
8.6. Polyclonal Antibody
9. Antibody Therapeutics Market, by Route of Administration
9.1. Introduction
9.2. Intravenous
9.3. Subcutaneous
10. Antibody Therapeutics Market, by Source
10.1. Introduction
10.2. Chimeric
10.3. Human
10.4. Humanized
11. Antibody Therapeutics Market, by Disease Areas
11.1. Introduction
11.2. Autoimmune & Inflammatory Diseases
11.3. Hematology
11.4. Immunology
11.5. Neurology
11.6. Oncology
11.7. Osteology
11.8. Rare Diseases
12. Antibody Therapeutics Market, by Application
12.1. Introduction
12.2. Diagnostics
12.3. Research
12.4. Therapeutics
13. Antibody Therapeutics Market, by End-User
13.1. Introduction
13.2. Hospitals
13.3. Research Institutes
13.4. Specialty Clinics
14. Americas Antibody Therapeutics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Antibody Therapeutics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Antibody Therapeutics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Adaptimmune Therapeutics PLC
17.3.3. Almac Group Limited
17.3.4. Amgen Inc.
17.3.5. Antikor Biopharma
17.3.6. Astellas Pharma Inc.
17.3.7. AstraZeneca PLC
17.3.8. Baxter International Inc.
17.3.9. Bayer AG
17.3.10. Becton, Dickinson and Company
17.3.11. Bio-Rad Laboratories, Inc.
17.3.12. Biogen Inc.
17.3.13. BioNTech SE
17.3.14. Bristol-Myers Squibb Company
17.3.15. Confo Therapeutics
17.3.16. DH Life Sciences, LLC
17.3.17. Eli Lilly and Company
17.3.18. F. Hoffmann-La Roche Ltd.
17.3.19. GlaxoSmithKline PLC
17.3.20. Grifols, S.A.
17.3.21. Incyte Corporation
17.3.22. Johnson & Johnson Services, Inc.
17.3.23. Merck KGaA
17.3.24. Novartis AG
17.3.25. Novo Nordisk A/S
17.3.26. Pfizer Inc.
17.3.27. Sanofi S.A.
17.3.28. Takeda Pharmaceutical Company Limited
17.3.29. Thermo Fisher Scientific Inc.
17.3.30. UCB S.A.
17.3.31. Xencor, Inc.
17.3.32. Kyowa Kirin Co., Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ANTIBODY THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. ANTIBODY THERAPEUTICS MARKET: RESEARCHAI
FIGURE 28. ANTIBODY THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 29. ANTIBODY THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 30. ANTIBODY THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTIBODY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY FRAGMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY FRAGMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES (ADCS), BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES (ADCS), BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OSTEOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OSTEOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 95. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 96. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 97. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 98. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 99. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 100. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 101. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 102. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 103. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 104. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 105. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 106. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 107. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 108. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 109. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 112. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 113. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 114. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 115. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 116. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 117. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 118. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 162. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 164. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 168. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 169. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 170. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 171. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 174. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 175. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 176. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 177. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 178. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 179. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 180. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 181. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 182. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 183. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 186. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 187. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 188. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 189. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 190. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 191. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 192. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 193. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 194. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 195. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 198. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 199. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 200. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 201. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 202. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 203. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 204. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 205. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 206. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 207. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 210. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 211. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 212. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 213. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 214. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 215. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 216. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 217. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 218. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 219. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 222. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 223. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 224. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 225. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 226. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 227. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 228. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 246. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 248. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 250. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 252. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 254. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 258. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 260. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 262. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 263. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 264. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 265. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 266. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 267. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 270. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 271. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 272. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 273. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 274. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 275. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 276. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 277. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 278. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 279. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 280. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 281. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 282. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 283. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 284. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 285. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 286. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 287. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 288. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 289. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 290. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 291. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 294. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 295. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 296. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 297. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 298. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 299. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 300. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 301. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 302. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 303. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 304. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 305. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 306. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 307. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 308. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 309. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 310. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 311. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 312. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 313. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 314. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 315. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 316. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 317. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 318. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 319. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 320. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 321. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 322. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 323. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 324. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 325. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 326. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 327. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 328. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 329. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 330. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 331. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2024 (USD MILLION)
TABLE 332. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2025-2030 (USD MILLION)
TABLE 333. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 334. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD M

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Antibody Therapeutics market report include:
  • AbbVie Inc.
  • Adaptimmune Therapeutics PLC
  • Almac Group Limited
  • Amgen Inc.
  • Antikor Biopharma
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biogen Inc.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Confo Therapeutics
  • DH Life Sciences, LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Grifols, S.A.
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • UCB S.A.
  • Xencor, Inc.
  • Kyowa Kirin Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages198
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 287.58 Billion
Forecasted Market Value ( USD ) by 2030 $ 518.32 Billion
Compound Annual Growth Rate12.4%
Regions CoveredGlobal
No. of Companies Mentioned33

Related Topics

Related Reports

Next Generation Antibody Therapeutics Market by Antibody Class, Target Indication, Technology Platform, Expression System, Development Stage, Route of Administration - Global Forecast 2025-2030 - Product Image

Next Generation Antibody Therapeutics Market by Antibody Class, Target Indication, Technology Platform, Expression System, Development Stage, Route of Administration - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Monoclonal Antibody Therapeutics Market by Indication, Antibody Type, Molecular Target, Production Technology, Route Of Administration, Distribution Channel, End User, Therapy Type - Global Forecast 2025-2030 - Product Image

Monoclonal Antibody Therapeutics Market by Indication, Antibody Type, Molecular Target, Production Technology, Route Of Administration, Distribution Channel, End User, Therapy Type - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Bispecific Antibody Therapeutics Contract Manufacturing - Global Strategic Business Report - Product Image

Bispecific Antibody Therapeutics Contract Manufacturing - Global Strategic Business Report

  • Report
  • 382 Pages
  • Global
From
Bispecific Antibody Therapeutics Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Bispecific Antibody Therapeutics Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 190 Pages
  • Global
From
Antibody Discovery - Market Insights, Competitive Landscape, and Market Forecast - 2032 - Product Image

Antibody Discovery - Market Insights, Competitive Landscape, and Market Forecast - 2032

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.